Associated Papers
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
41326340 (PubMed )
Supplement: 41392_2025_2481_MOESM1_ESM.docx
The Pathogenic Mechanisms of and Novel Therapies for Lamin A/C-Related Dilated Cardiomyopathy Based on Patient-Specific Pluripotent Stem Cell Platforms and Animal Models.
Wu XY et al.
Pharmaceuticals (basel, Switzerland), 2024
Activating mutations drive human MEK1 kinase using a gear-shifting mechanism.
Patil K et al.
The Biochemical Journal, 2023
How oncogenic mutations activate human MAP kinase 1 (MEK1): a molecular dynamics simulation study.
Liu Y et al.
Journal of Biomolecular Structure & Dynamics, 2020
Mutations That Confer Drug-Resistance, Oncogenicity and Intrinsic Activity on the ERK MAP Kinases-Current State of the Art.
Smorodinsky-Atias K et al.
Cells, 2020
Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties.
Gao Y et al.
Cancer Discovery, 2018
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
Nikolaev SI et al.
Nature Genetics, 2011
Select a paper to view details